Intranasal Multiepitope PD-L1-siRNA-Based Nanovaccine: The Next-Gen COVID-19 Immunotherapy.

Acúrcio RC, Kleiner R, Vaskovich-Koubi D, Carreira B, Liubomirski Y, Palma C, Yeheskel A, Yeini E, Viana AS, Ferreira V, Araújo C, Mor M, Freund NT, Bacharach E, Gonçalves J, Toister-Achituv M, Fabregue M, Matthieu S, Guerry C, Zarubica A, Aviel-Ronen S, Florindo HF, Satchi-Fainaro R

Open source

DOI: 10.1002/advs.202404159
Published: 2024 Oct
Container: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/advs.202404159,
  title = {Intranasal Multiepitope PD-L1-siRNA-Based Nanovaccine: The Next-Gen COVID-19 Immunotherapy.},
  author = {Acúrcio RC and Kleiner R and Vaskovich-Koubi D and Carreira B and Liubomirski Y and Palma C and Yeheskel A and Yeini E and Viana AS and Ferreira V and Araújo C and Mor M and Freund NT and Bacharach E and Gonçalves J and Toister-Achituv M and Fabregue M and Matthieu S and Guerry C and Zarubica A and Aviel-Ronen S and Florindo HF and Satchi-Fainaro R},
  year = {2024},
  journal = {Advanced science (Weinheim, Baden-Wurttemberg, Germany)},
  doi = {10.1002/advs.202404159},
  url = {https://doi.org/10.1002/advs.202404159}
}

RIS

TY  - JOUR
TI  - Intranasal Multiepitope PD-L1-siRNA-Based Nanovaccine: The Next-Gen COVID-19 Immunotherapy.
AU  - Acúrcio RC
AU  - Kleiner R
AU  - Vaskovich-Koubi D
AU  - Carreira B
AU  - Liubomirski Y
AU  - Palma C
AU  - Yeheskel A
AU  - Yeini E
AU  - Viana AS
AU  - Ferreira V
AU  - Araújo C
AU  - Mor M
AU  - Freund NT
AU  - Bacharach E
AU  - Gonçalves J
AU  - Toister-Achituv M
AU  - Fabregue M
AU  - Matthieu S
AU  - Guerry C
AU  - Zarubica A
AU  - Aviel-Ronen S
AU  - Florindo HF
AU  - Satchi-Fainaro R
PY  - 2024
JO  - Advanced science (Weinheim, Baden-Wurttemberg, Germany)
DO  - 10.1002/advs.202404159
UR  - https://doi.org/10.1002/advs.202404159
ER  -

APA

RC, A., R, K., D, V., B, C., Y, L., C, P., A, Y., E, Y., AS, V., V, F., C, A., M, M., NT, F., E, B., J, G., M, T., M, F., S, M., C, G., A, Z., S, A., HF, F., & R, S. (2024). Intranasal Multiepitope PD-L1-siRNA-Based Nanovaccine: The Next-Gen COVID-19 Immunotherapy.. Advanced science (Weinheim, Baden-Wurttemberg, Germany). https://doi.org/10.1002/advs.202404159

Source records

pubmed · retrieved 2026-09-26T03:40:35.505Z